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Summary
Background Indirect financial costs and barriers to health-care access might contribute to leprosy treatment non-
adherence. We estimated the association of the Brazilian conditional cash transfer programme, the Programa Bolsa 
Família (PBF), on leprosy treatment adherence and cure in patients in Brazil.
Methods In this quasi-experimental study, we linked baseline demographic and socioeconomic information for 
individuals who entered the 100 Million Brazilian Cohort between Jan 1, 2007, and Dec 31, 2014, with the PBF payroll 
database and the Information System for Notifiable Diseases, which includes nationwide leprosy registries. Individuals 
were eligible for inclusion if they had a household member older than 15 years and had not received PBF aid or been 
diagnosed with leprosy before entering the 100 Million Brazilian Cohort; they were excluded if they were partial receivers 
of PBF benefits, had missing data, or had a monthly per-capita income greater than BRL200 (US$50). Individuals who 
were PBF beneficiaries before leprosy diagnosis were matched to those who were not beneficiaries through propensity-
score matching (1:1) with replacement on the basis of baseline covariates, including sex, age, race or ethnicity, education, 
work, income, place of residence, and household characteristics. We used logistic regression to assess the average 
treatment effect on the treated of receipt of PBF benefits on leprosy treatment adherence (six or more multidrug therapy 
doses for paucibacillary cases or 12 or more doses for multibacillary cases) and cure in individuals of all ages. We 
stratified our analysis according to operational disease classification (paucibacillary or multibacillary). We also did a 
subgroup analysis of paediatric leprosy restricted to children aged up to 15 years.
Findings We included 11 456 new leprosy cases, of whom 8750 (76·3%) had received PBF before diagnosis and 
2706 (23·6%) had not. Overall, 9508 (83·0%) patients adhered to treatment and 10 077 (88·0%) were cured. After 
propensity score matching, receiving PBF before diagnosis was associated with adherence to treatment (OR 1·22, 
95% CI 1·01–1·48) and cure (1·26, 1·01–1·58). PBF receipt did not significantly improve treatment adherence 
(1·37, 0·98–1·91) or cure (1·12, 0·75–1·67) in patients with paucibacillary leprosy. For patients with multibacillary 
disease, PBF beneficiaries had better treatment adherence (1·37, 1·08–1·74) and cure (1·43, 1·09–1·90) than 
non-beneficiaries. In the propensity score-matched analysis in 2654 children younger than 15 years with leprosy, 
PBF exposure was not associated with leprosy treatment adherence (1·55, 0·89–2·68) or cure (1·57, 0·83–2·97).
Interpretation Our results suggest that being a beneficiary of the PBF, which facilitates cash transfers and improved 
access to health care, is associated with greater leprosy multidrug therapy adherence and cure in multibacillary cases. 
These results are especially relevant for patients with multibacillary disease, who are treated for a longer period and 
have lower cure rates than those with paucibacillary disease.
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Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Leprosy, also known as Hansen’s disease, is a neglected 
tropical disease that affects more than 200 000 individuals 
worldwide annually and is a leading infectious cause 
of permanent physical disability.1,2 As the burden of 
leprosy-associated disability can be mitigated through 
timely detection and treatment, WHO has supplied 
free multidrug therapy to health systems in high-burden 
countries since 1995.1 WHO recommends a 6-month 
treatment regimen for patients with paucibacillary leprosy 
(ie, those with five lesions or fewer), comprising daily 
doses of dapsone.1 For patients with multibacillary leprosy 
(ie, those with more than five lesions or a positive slit-skin 
smear), the recommendation comprises a 12-month treat-
ment regimen with daily combined doses of dapsone and 
clofazimine. For both operational classifications of the 
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disease, the daily treatments are accompanied by once-
monthly doses of rifampicin administered under super-
vision.1 Not completing the prescribed treat ment regimens 
for leprosy can contribute to ongoing trans mission, 
stigmatised disabilities, and antimicrobial resist ance.3
Individuals living in poor socioeconomic conditions in 
low-income and middle-income countries are dispro-
portionately affected by leprosy.4 In Brazil, the country 
with the second-highest number of leprosy cases world-
wide after India, individuals with poor socio economic 
status and unfavourable living conditions have a sub-
stantially increased risk of being newly diagnosed with 
leprosy.5 Additionally, adverse socioeconomic factors 
might influence adherence and completion of leprosy 
treatment. A 2009 population-based survey in northern 
Brazil found a positive association between non-
adherence and dropout from leprosy treatment and the 
poverty-related characteristics of low familial income, 
fewer rooms per household, and migration.3 Further-
more, a 2016 population-based survey in China reported 
that a leprosy diagnosis can incur large financial costs 
(ie, up to 38% of annual household income) and 
lead to job insecurity, which could exacerbate the risks 
of treatment dropout.6 Additionally, a 2013 systematic 
review found that health-service engagement with 
patients with leprosy has been associated with 
increased retention in care in India, Brazil, and the 
Philippines.7
Worldwide, conditional cash transfer programmes, 
including the Brazilian Government’s social welfare 
Programa Bolsa Família (family allowance programme; 
PBF) implemented in 2004, have benefitted recipient 
families by reducing poverty,8 improving health-care use,9,10 
and increasing cure rates for chronic infections such as 
tuberculosis.11–15 Although increased PBF coverage has 
been associated with reduced leprosy incidence in 
Brazilian municipalities,16,17 the influence of conditional 
cash transfers on leprosy treatment patterns is unknown. 
We hypothesised that participation in the PBF has the 
potential to increase leprosy treatment adherence and cure 
by reducing the financial consequences of a leprosy 
diagnosis and strengthening the interaction of patients 
with health services (figure 1).10,18 Using prospective 
data from more than 10 000 patients with leprosy in 
the 100 Million Brazilian Cohort, we investigated the 
association of the PBF with indicators of retention in care. 
Specifically, we evaluated whether patients with leprosy 
who began receiving cash transfers from the PBF before 
their diagnosis were more likely to complete the prescribed 
multidrug therapy regimen and be cured than their 
Research in context
Evidence before this study
In low-income and middle-income countries, social protection 
policies have been associated with better tuberculosis treatment 
outcomes. To investigate the available evidence of the effect of 
such programmes on leprosy, we searched PubMed and Embase 
for studies published in any language between Jan 1, 1990, and 
April 18, 2019, containing the following terms: (“financial 
support” [MeSH Term] OR “cash transfer program” OR “cash 
transfer” OR “public assistance” [MeSH Term] OR “social 
protection” OR “monetary incentive” OR “social programs” OR 
“food assistance” OR “food program” OR “social policies” OR 
“social policy” OR “safety nets” OR “ in-kind transfers”) AND 
(“leprosy” OR leprosy[MeSH Terms] OR “Hansen”). We found 
628 records and identified only two relevant studies that 
evaluated any associations between receiving social protection 
benefits and leprosy incidence, prevalence, related disabilites, 
and treatment outcomes. Both studies had an ecological design 
and evaluated the association between the conditional cash 
transfer programme Programa Bolsa Família (PBF) and leprosy 
incidence in Brazil at the municipality level. One study focused 
on the effect of the programme on children younger than 
15 years. Both studies found an approximately 15% reduced 
leprosy incidence in municipalities with high coverage of PBF, 
but neither evaluated its effect on treatment adherence or cure.
Added value of this study
To our knowledge, this is the first study to evaluate the 
association between a policy aiming to reduce poverty and 
leprosy treatment outcomes. By linking nationwide data 
from individuals applying for social programmes in Brazil and 
analysing data from more than 11 000 new leprosy cases, our 
study has unprecedented statistical power to study leprosy 
treatment outcomes. Using a causal inference framework of 
analysis and propensity score methods to control for 
socioeconomic and demographic characteristics, we found that 
receiving PBF benefits was associated with improved adherence 
to multidrug therapy treatment and increased cure rates. 
Our results show the public health potential of using linked 
administrative datasets to study the effect of social policies on 
the outcomes of rare diseases, including neglected tropical 
diseases, and provide new evidence of a potential beneficial 
effect of cash transfer programmes on leprosy treatment 
and control.
Implications of all the available evidence
To policymakers, our study contributes to the evidence base 
that programmes that mitigate poverty might bolster leprosy 
control and should be considered essential tools for helping 
countries to achieve the goals outlined in the WHO Global 
Leprosy Strategy 2016−2020. Although further research is 
needed to identify the specific mechanisms by which 
participation in cash transfer programmes improves adherence 
to treatment and cure in patients with leprosy, this study 
indicates that cash transer or in-kind social assistance 
programmes have the potential to improve leprosy 
treatment outcomes.
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counterparts who did not benefit from the PBF 
programme.1
Methods
Study design and participants
In this quasi-experimental study, we included newly 
diagnosed patients with leprosy detected among individuals 
who entered the 100 Million Brazilian Cohort between Jan 
1, 2007, and Dec 31, 2014, the time period for which data on 
leprosy were available. We considered individuals as 
exposed to the PBF intervention if they had started receiving 
PBF benefits before their leprosy diagnosis and continued 
receiving benefits during the entire duration of treatment. 
Individuals who never received PBF aid over the duration 
of multidrug therapy treatment were considered to be 
unexposed to the PBF intervention.
Newly diagnosed patients were included in our analysis 
if they had a household member older than 15 years (to 
exclude children registered separately from any adult 
family members), and had not received PBF, nor had 
been diagnosed with leprosy before entering the 
100 Million Brazilian Cohort. After selecting patients who 
met these conditions, we excluded individuals who were 
partial receivers of PBF benefits (ie, who stopped 
receiving PBF benefits either before diagnosis or during 
treatment), had missing data for the outcome variables 
and baseline familial sociodemographic covariates, or 
had a monthly per-capita income greater than BRL200 
(US$50; ie, the highest quartile of incomes in the 
100 Million Brazilian Cohort) at baseline.
This study was done under the Declaration of Helsinki 
and the Brazilian and UK research regulations and was 
approved by the three research ethics committee of 
the University of Brasília (Brasília, Brazil; 1.822.125), 
Instituto Gonçalo Muniz (Salvador, Brazil; 1.612.302), 
and London School of Hygiene & Tropical Medicine 
(London, UK; 10580-1). The 100 Million Brazilian Cohort 
has waived the need for informed consent, as it has been 
built through the linkage of administrative databases.
Data sources
Data on newly diagnosed patients with leprosy from the 
100 Million Brazilian Cohort were identified through the 
linkage of the baseline of the 100 Million Brazilian Cohort 
and the Information System for Notifiable Diseases 
(SINAN) of the Brazilian Ministry of Health. Information 
on PBF receipt was obtained through the linkage of the 
baseline of the 100 Million Brazilian Cohort and the PBF 
payroll database. The full linked cohort was provided by 
the Centre for Data and Knowledge Integration for Health 
(CIDACS; Salvador, Brazil).19,20
The baseline of the 100 Million Brazilian Cohort was 
built from the initial application of families and their 
family members for social assistance programmes in 
Brazil through the registration with the national 
administrative database Cadastro Único para Programas 
Sociais (CadÚnico) from Jan 1, 2001, to Dec 31, 2015.21 
Individuals aged 16 years and older can subscribe to 
CadÚnico, and on registration, individual (ie, sex, age, 
race or ethnicity, education, and work status) and 
familial (ie, familial income, household density, and 
housing characteristics) sociodemographic information 
is collected.21
Families registered in CadÚnico are eligible to receive 
PBF funding if they are extremely poor (ie, receiving 
≤BRL60 [approximately $15·0] monthly per capita 
in 2007–08 and ≤BRL70 [$17·5] monthly per capita 
in 2009–14) or poor (ie, ≤BRL120 [$30·0] monthly per 
capita in 2007–08 and ≤BRL140 [$35·0] monthly per 
capita in 2009–14) and have children (≤17 years old), 
pregnant women, or breastfeeding women in the house-
hold.21 Eligible families receive a monthly cash transfer 
conditional on school attendance of all children, health 
monitoring and vaccination for children aged up to 
6 years, and attendance of prenatal and postnatal care for 
women. Social assistants monitor families receiving PBF 
benefits to ensure compliance, and the income benefit 
is suspended only after a minimum of 2 years of 
non-compliance.21 We extracted information from the 
PBF payroll database about the date of the first and last 
payments transferred to families from Jan 1, 2004, to 
Dec 31, 2015.
SINAN is a decentralised surveillance system, operated 
in partnership with health-care professionals in all 
health-care facilities, that monitors the incidence of 
notifiable diseases and collects data to inform the 
provisioning of health services and resources. When a 
Figure 1: Hypothetical model of the potential pathways by which the Programa Bolsa Família might affect 
leprosy treatment adherence and cure
Black arrows indicate factors known to be affected directly (ie, individual socioeconomic conditions), whereas red 
arrows indicate factors that might affect leprosy treatment adherence and cure.
Programa Bolsa Família 
Effect of Programa Bolsa Família on the community 
Spillover effects on the community (eg, local
social, devleopment)
Social welfare services
Economic 
inclusion (employment)
Cash (income)
Conditionalities
Effect of Programa Bolsa
Família on individuals
Fnancial planning and
stability
Food security Improved household
conditions
Access to maternal 
and child health-
care
Health-care access
Treatment adherence
Leprosy cureLeprosy infection Leprosy disease
Paucibacillary
Multibacillary
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leprosy diagnosis is made, health professionals collect 
socio demographic (ie, sex, age, race or ethnicity, 
education, and work status) and clinical (ie, date of 
diagnosis and case type [new or relapsed]) information, 
operational classification (paucibacillary or multibacillary 
disease), and grade of disabilities at diagnosis (0, 1, 
and 2). Multidrug therapy data are recorded during and 
after treatment and include the dates of treatment 
initiation and last visit, the number of doses taken, 
and the treatment outcome (ie, cure, transferred away, 
dropout, or death). We extracted socio demographic, 
clinical, and treatment data on all new leprosy cases that 
were notified to SINAN between Jan 1, 2007, and 
Dec 31, 2014.
Dataset linkage
Data extraction and linkage procedures were done at 
CIDACS. The 100 Million Brazilian Cohort (baseline 2001–
15) and PBF payroll database (2004–15) were linked using 
exact deterministic linkage through each individual’s 
Number of Social Identification, a unique identifier. 
The Cohort’s baseline and SINAN (available leprosy 
data 2007–14) were deterministically linked using the 
CIDACS-RL tool, an open-source record linkage tool 
registered in GitHub, which gen erates a similarity score on 
the basis of five individual identifiers: name, date of birth, 
sex, name of mother, and the municipality of residence.22 
Linkage accuracy was evaluated by two independent 
researchers who manually reviewed 10 000 randomly 
selected linked pairs from different score strata to verify the 
proportion of true and false matched pairs in each strata.23 
Random selection was done using a computer-generated 
randomised sample using R software. Disagreement was 
resolved by a third senior researcher. Sensitivity and 
specificity were assessed for various threshold of the 
similarity score. The best performing score threshold that 
was selected for use in our analysis (≥0·92) achieved a 
specificity of 0·89 (95% CI 0·88–0·90) and sensitivity of 
0·91 (95% CI 0·90–0·92; data not shown).
Outcomes
Outcomes of interest were leprosy treatment adherence 
and cure. According to WHO guide lines, leprosy 
treatment is completed when patients finish a 6-month 
multidrug therapy regimen in 9 months or fewer 
for paucibacillary leprosy or a 12-month regimen in 
18 months or fewer for multi bacillary leprosy.1 In 
Brazil, leprosy cure is recorded by health professionals 
in SINAN when these guidelines are met, but 
additional multidrug therapy doses can be prescribed 
in the absence of clinical improvements on the 
clinician’s discretion.24 We defined leprosy treatment 
adherence as achieving the prescribed number of 
multidrug therapy doses (ie, six or more doses for 
paucibacillary disease and 12 or more doses for 
multibacillary disease) and leprosy cure as recorded by 
health professionals.
Statistical analysis
We used propensity score matching to estimate the 
effect of PBF aid receipt on leprosy treatment outcomes. 
We used logistic regression to estimate the propensity 
scores of receiving PBF aid, considering all of the 
following baseline demographic and socioeconomic 
covariates collected before receipt of aid and leprosy 
diagnosis: sex, age, race or ethnicity, education, work, 
per-capita income, household density, geographic 
region, area of residence (urban vs rural), housing 
ownership, housing construction material, electricity, 
water supply, and sewage and waste disposal. We 
considered the education and work characteristics of 
individuals younger than 18 years to be represented by 
the oldest member in the family (as a proxy for the 
family head). For individuals enrolling into the 
100 Million Brazilian Cohort after Aug 31, 2009, we 
divided the per-capita income by 1·167 to account for the 
same rate of change in the eligibility criteria for the PBF. 
Variables were selected a priori for inclusion in the fully 
adjusted model on the basis of potential con founders 
for the association between PBF aid and lep rosy 
treatment outcomes (ie, adjustment for all variables was 
made simultaneously).
We matched beneficiaries and non-beneficiaries (1:1) 
using nearest-neighbour matching with replacement 
and a caliper of 0·05.25 Missing data in individual socio-
demographic covariates, which we assumed were poten-
tially stronger confounders of the association between 
PBF aid and the individually measured out comes than 
the covariates assessed at the familial level, were included 
as a category. We assessed the balance in the distribution 
of covariates before and after matching using stan-
dardised mean difference (a difference of <0·1 after 
matching was considered to indicate a good balance). 
Propensity-score estimation and matching were done for 
the overall sample and for paucibacillary and multi-
bacillary cases separately. We estimated the average 
treatment effect on the treated (ATT) by calculating the 
odds ratio in each matched dataset using logistic 
regression, with further adjustment for income as a 
continuous variable, using robust SEs clustered by 
individual to account for matching with replacement.26 
Additionally, as paediatric leprosy diagnoses indicate 
relatively high endemicity and active transmission,27 we 
did a subgroup analysis in children who were younger 
than 15 years at the time of leprosy diagnosis, as this age 
threshold is used by the Brazilian Ministry of Health and 
WHO as an indicator of leprosy control. These analyses 
were done in all individuals who met the study inclusion 
criteria.
We did sensitivity analyses related to our analytical 
approach and the definition of cure. First, we used the 
inverse probability of treatment weighting (IPTW) to 
estimate the ATT of PBF on leprosy treatment outcomes. 
For this analysis, the effect of PBF aid on treatment 
adherence and cure was estimated using logistic 
For the CIDACS-RL tool via 
GitHub see https://gitHub.com/
gcgbarbosa/cidacs-rl
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re gression, weighting non-beneficiaries with the formula 
propensity score / (1–propensity score) and beneficiaries 
as 1, with further adjustment for income. This analysis 
was done for the overall population and for individuals 
younger than 15 years. Second, to investigate the robust-
ness of our conclusions regarding the way in which 
missing data in studied covariates were handled, we did a 
complete case analysis (ie, restricting the analysis to 
individuals without missing data for any of the covariates 
included in the propensity score). Third, to test if the 
results are robust regarding the definition of cure, we 
excluded individuals recorded as cured in SINAN who 
had not completed the minimum number of multidrug 
therapy doses for each operational classification form of 
the disease and re-estimated the effect in the overall 
population, using both propensity-score matching and 
IPTW with the propensity score. All analyses were done 
using STATA version 15.0 and R version 3.5.2.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to the data and had final responsibility for the 
decision to submit for publication.
Results
From 2001 to 2015, the 100 Million Brazilian 
Cohort baseline linked with the PBF payroll database 
included socio economic and PBF information on 
114 008 179 individuals (figure 2). When these individuals 
were linked with the SINAN database, we identified 
46 456 cases of leprosy among 37 385 406 individuals who 
entered the 100 Million Brazilian Cohort between 2007 
and 2014 (representing 16·4% of all 282 733 new cases of 
leprosy recorded in SINAN in that period; figure 2). After 
excluding 23 547 participants who did not meet the 
inclusion criteria, we also excluded those who met the 
exclusion criteria (n=11 453). The study sample included 
only the 11 456 patients with newly diagnosed leprosy 
(24·6% of the 46 456 linked cases) who were diagnosed 
with leprosy after entering the 100 Million Brazilian 
Cohort and met all other eligibility criteria.
8750 (76·4%) of 11 456 patients with leprosy 
began receiving PBF aid before their diagnosis and 
2706 (23·6%) patients were not PBF beneficiaries by the 
time of leprosy diagnosis, treatment completion, or 
dropout. Relative to the 11 453 patients with newly 
diagnosed leprosy who were not included in the analysis 
because of being partial benefit receivers or having 
missing data or an income greater than BRL200 (figure 2), 
the included patients were younger, with a higher 
proportion of women and lower monthly familial and 
per-capita income (appendix pp 1, 2). PBF beneficiaries 
and non-beneficiaries differed by demographic and 
socioeconomic characteristics at entry to the 100 Million 
Brazilian Cohort (table 1).
5140 (44·9%) of 11 456 leprosy cases were paucibacillary 
leprosy and 6316 (55·1%) were multibacillary leprosy 
(table 2). Of 1726 children younger than 15 years, 
1089 (63·1%) had paucibacillary leprosy and 637 (36·9%) 
had multibacillary leprosy (table 2). Treatment adherence 
in the cohort was high overall, and higher in paucibacillary 
cases than in multibacillary cases (table 2). Overall, 
10 077 (88·0%) individuals were reported to have been 
cured of leprosy in SINAN. A higher proportion of patients 
with paucibacillary disease than with multibacillary disease 
were classified as cured (91·1% vs 85·4%). Rates of 
treatment adherence and cure were similar for children, 
for individuals of all ages overall, and for disease 
operational classification (table 2).
After estimating the propensity score for receiving 
PBF on the basis of selected covariates for the overall 
population and for children younger than 15 years 
(appendix pp 4–7), we observed sufficient overlap in the 
propensity score distributions for PBF beneficiaries and 
non-beneficiaries (appendix p 12). Matching by pro-
pensity score resulted in 98·9% successfully matched 
pairs (8651 of 8750 beneficiaries) in the general 
Figure 2: Flow diagram
CadÚnico=Cadastro Único para Programas Sociais. PBF=Programa Bolsa Família.
114 008 179 individuals in the 100 Million Brazilian Cohort baseline (2001–15) 
deterministically linked with the PBF payroll database (2004–15)
37 385 406 applicants to the 100 Million Brazilian Cohort after baseline in
                        2007–14
46 456 patients withnewly diagnosed leprosy among applicants to the
                100 Million Brazilian Cohort in 2007–14
22 909 newly diagnosed patients with leprosy eligible for  the analysis
11 456 newly diagnosed patients with leprosy included in the analysis
113 961 723 individuals excluded because they did not have leprosy 
and/or were not applicants to CadÚnico for 2007–14
23 547 patients with leprosy excluded
808 no family member was older than 15 years at 
registration
1574 family started receiving PBF aid before 2007 
 or before entering the Cohort
21 165 diagnosed with leprosy before entering the 
  Cohort
11 453 patients with leprosy excluded
3699 partial receivers of PBF aid (i.e, they stopped 
receiving PBF before diagnosis or did not 
receive PBF for the full duration of treatment)
2312 missing values for outcome variables
2113 missing values for familial variables
3329 income >200 BRLz
See Online for appendix
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population and 87·1% (1327 of 1524 beneficiaries) in 
children. Matching substantially increased the similarity 
between PBF and non-PBF recipients: the standardised 
mean difference between both groups was lower than 
0·1 for most covariates (appendix pp 7, 8).
In the overall matched dataset including all ages, 
patients receiving PBF benefits before leprosy diagnosis 
had better treatment adherence than those who did not 
(OR 1·22, 95% CI 1·01–1·48). Similarly, PBF beneficiaries 
had higher odds of leprosy cure than non-beneficiaries 
(1·26, 1·01–1·58; table 3).
In multibacillary cases, PBF exposure was associated 
with increased treatment adherence (ie, receiving 
≥12 multidrug therapy doses) and cure (table 3). In 
paucibacillary cases, PBF exposure was not significantly 
associated with treatment adherence (ie, receiving at 
least six multidrug therapy doses) or cure. In the 
subgroup analysis of 1327 matched pairs of children 
younger than 15 years at diagnosis, there was no 
association between PBF exposure and leprosy treatment 
adherence or cure (table 3).
The sensitivity analysis with IPTW yielded similar 
results to the propensity-score matched analysis, with no 
indication of differences in the associations between PBF 
and adherence and cure in the overall population and in 
children (table 3). In the complete case analysis, we 
included only the 9960 individuals without missing data 
for any of the propensity score covariates. After matching 
with replacement (n=15 130), we detected no associations 
with treatment adherence (OR 1·17, 95% CI 0·95–1·43) 
or cure (1·20, 0·94–1·52), but analysis using IPTW 
yielded similar results to the primary analysis 
(appendix p 9).
We did further sensitivity analyses excluding 
662 individuals (6% of the original cohort) who had not 
completed the minimum recommended number of 
doses but were considered cured by the clinician 
(appendix p 10). Using propensity-score matching, we 
found no evidence for an association between receiving 
PBF and treatment adherence in the overall population 
(OR 1·14, 95% CI 0·91–1·43). However, an association 
between between receipt of PBF and treatment 
adherence remained for multibacillary cases (1·48, 
1·14–1·90). Similarly, the association between receiving 
PBF and leprosy cure was lost in the overall population 
(1·08, 0·87–1·35), but the association of PBF with 
cure remained evident for multibacillary cases (1·40, 
1·09–1·79). Results were consistent between propensity-
score matching and IPTW analyses (appendix p 10).
Discussion
Using data on more than 11 000 patients with leprosy 
participating in the 100 Million Brazilian Cohort, we 
investigated the effect of a conditional cash transfer 
programme on leprosy treat ment outcomes. Overall, we 
found evidence that PBF participation was associated 
with a 22% improvement in leprosy treatment adherence 
Non-beneficiaries 
(n=2706)
Beneficiaries 
(n=8750)
p value*
Individual variables
Age at registration, years 39·1 (26·7–53·6) 29·5 (20·3–40·7) <0·0001
Age at diagnosis, years 41·4 (28·6–55·6) 32·9 (23·4–44·0) <0·0001
Children ·· ·· <0·0001
Younger than 15 years 202/1726 (11·7%) 1524/1726 (88·3%) ··
Aged 15 years and older 2504/9730 (25·7%) 7226/9730 (74·3%) ··
Sex ·· ·· 0·0026
Male 1344 (49·7%) 4054 (46·3%) ··
Female 1362 (50·3%) 4696 (53·7%) ··
Race or ethnicity ·· ·· <0·0001
White 528 (19·5%) 1356 (15·5%) ··
Non-white (Asian, Indigenous, Black, 
and Mixed Black)
2133 (78·8%) 7272 (83·1%) ··
Missing data 45 (1·7%) 122 (1·4%) ··
Education ·· .. <0·0001
Illiterate 421 (15·6%) 1214 (13·9%) ··
Primary school or less (≤5 years of 
education)
1018 (37·6%) 3273 (37·4%) ··
Junior high school (≤9 years of 
education)
624 (23·1%) 2530 (28·9%) ··
High school (≥10 years of education) 311 (11·5%) 821 (9·4%) ··
Missing data 332 (12·3%) 912 (10·4%) ··
Work ·· ·· <0·0001
Employed 1289 (47·6%) 4802 (54·9%) ··
Unemployed 1392 (51·4%) 3828 (43·7%) ··
Missing 25 (0·9%) 120 (1·4%) ··
Clinical variables
Operational disease classification ·· ·· 0·020
Paucibacillary 1161 (42·9%) 3979 (45·5%) ··
Multibacillary 1545 (57·1%) 4771 (54·5%) ··
Disabilities at diagnosis ·· ·· 0·059
Grade 0 1754 (64·8%) 5904 (67·5%) ··
Grade 1 566 (20·9%) 1644 (18·8%) ··
Grade 2 147 (5·4%) 454 (5·2%) ··
Not evaluated or missing 239 (8·8%) 748 (8·5%) ··
Familial variables
Region of residence ·· ·· <0·0001
North 639 (23·6%) 2310 (26·4%) ··
Northeast 1108 (40·9%) 3887 (44·4%) ··
Southeast 362 (13·4%) 1165 (13·3%) ··
South 86 (3·2%) 136 (1·6%) ··
Midwest 511 (18·9%) 1252 (14·3%) ··
Area of residence ·· ·· <0·0001
Urban 2193 (81·0%) 6613 (75·6%) ··
Rural 513 (19·0%) 2137 (24·4%) ··
Type of household ·· ·· 0·023
Private 2663 (98·4%) 8545 (97·7%) ··
Shared and informal housing 43 (1·6%) 205 (2·3%) ··
Construction material of household ·· ·· <0·0001
Bricks or cement 1954 (72·2%) 5687 (65·0%) ··
Wood, other vegetal materials, or other 752 (27·8%) 3063 (35·0%) ··
(Table 1 continues on next page)
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and 26% improvement in cure if enrolment in PBF 
occurred before diagnosis.
In patients with multibacillary disease who were 
receiving PBF benefits, we observed 43% higher cure 
rates than in patients with multibacillary disease who 
were non-beneficiaries. This finding is of potentially 
high public health importance as, relative to paucibacillary 
cases, multibacillary cases require longer treatment 
durations and, in our study, had lower cure rates overall 
(91·1% for paucibacillary vs 85·4% for multibacillary 
cases, table 2). Notably, the multibacillary cure rates were 
below the targets for cure (>90%) set by Brazilian states 
and municipalities.28 Moreover, multibacillary cases 
are associated with greater risks of transmission and 
progression to disabilities than are paucibacillary cases.29 
Although relapses of leprosy disease are rare, they are 
most commonly reported in patients with multibacillary 
disease and have the potential to increase antimicrobial 
resistance.30 Hence, improvements to multibacillary 
treatment adherence and cure are of particular value for 
reducing the public health burden attributed to leprosy.
Our results add to the scant evidence base on the effects 
of social policies on leprosy, which currently consists of 
two ecological studies done in Brazil.16,17 One study found 
the leprosy incidence in children younger than 15 years to 
be 15% lower in municipalities with high PBF coverage 
(≥50% coverage) than in municipalities with low coverage 
after adjusting for primary care coverage and socio-
economic characteristics.17 The other study reported 
leprosy incidence in the overall population to be up to 
21% lower than in municipalities with low coverage when 
PBF coverage was maintained at high levels (>48%) for 
more than 4 years.16
Our findings align with results from previous studies 
investigating the effects of social protection programmes 
on treatment outcomes for other infectious diseases.11–13 
A 2015 Liberian study of a community health worker 
programme providing transportation reimbursements, 
food support, and cash transfers found that it facilitated 
access to care and treatment adherence for patients with 
tuberculosis and HIV, although the study had insufficient 
power to analyse the effect of the programme on patients 
with leprosy.31 Furthermore, a systematic review and 
meta-analysis of nine social protection programmes, of 
which two were cash transfer programmes, showed a 
37% reduction in risk of default on tuberculosis treatment 
and an 11% increase in tuberculosis cure rate in 
beneficiaries.14 Moreover, the PBF specifically has been 
associated with improved tuberculosis treatment outcomes 
in several studies.11–13 In two studies using CadÚnico and 
tuberculosis registry data and propensity score matching 
analyses, PBF receipt was associated with an increased 
tuberculosis cure rate.11,12 Similarly, a multicentre pros-
pective study done across seven Brazilian cities found that 
PBF beneficiaries had a higher tuberculosis cure rate and a 
lower risk of treatment dropout and death than propensity 
score-matched non-beneficiaries.13
Non-beneficiaries 
(n=2706)
Beneficiaries 
(n=8750)
p value*
(Continued from previous page)
Water supply ·· ·· <0·0001
Public network (tap water) 1929 (71·3%) 5520 (63·1%) ··
Well, natural sources, or other 777 (28·7%) 3230 (36·9%) ··
Electricity ·· ·· <0·0001
Yes (with counter) 2347 (86·7%) 6899 (78·8%) ··
Electricity without counter or no 
electricity
359 (13·3%) 1851 (21·2%) ··
Sewerage ·· ·· <0·0001
Public network or septic tank 1479 (54·7%) 4241 (48·5%) ··
Homemade septic tank, ditch, or other 1227 (45·3%) 4509 (51·5%) ··
Waste ·· ·· <0·0001
Public collection system 2122 (78·4%) 6255 (71·5%) ··
Burned, buried, outdoor disposal, or 
other
584 (21·6%) 2495 (28·5%) ··
Individuals per family 3 (2–4) 3 (2–4) <0·0001
Residents per room 0·67 (0·50–1·00) 1·00 (0·67–1·33) <0·0001
Monthly family income, BRL 200 (100–390) 150 (80–270) <0·0001
Monthly per-capita income adjusted for 
PBF threshold, BRL†
80·0 (40·0–136·8) 43·3 (23·3–70·0) <0·0001
Data are n (%) or median (IQR). Leprosy-related disabilities at diagnosis were classified as grade 0 if there was no presence 
of visible disabilities, grade 1 if there were signs of eye problems or anaesthesia in the hands and feet, and grade 2 if there 
was severe visual impairment or visible deformity or damage in the hands and feet. PBF=Programa Bolsa Família. *p values 
calculated for a two-tailed t test for comparison of continuous variables and Pearson’s χ2 for categorical variables. †As the 
income threshold for eligibility increased by 1·167 in August, 2009, the monthly per-capita income was divided by 
1·167 for families registering with CadÚnico after August, 2009, in this study.
Table 1: Characteristics of patients with newly diagnosed leprosy who entered the 100 Million Brazilian 
Cohort between 2007 and 2014, according to receipt of PBF aid
Total Paucibacillary Multibacillary
Overall population
Patients, n 11 456 5140 6316
Months between diagnosis and end of 
treatment
10·1 
(5·9–12·4)
6·1 
(5·5–7·4)
11·8 
(10·8–13·3)
Treatment adherence*
No 1948 (17·0%) 648 (12·6%) 1300 (20·6%)
Yes 9508 (83·0%) 4492 (87·4%) 5016 (79·4%)
Cure
No (death, transfer of health unit, default) 1379 (12·0%) 459 (8·9%) 920 (14·6%)
Yes 10 077 (88·0%) 4681 (91·1%) 5396 (85·4%)
Children younger than 15 years
Patients, n 1726 1089 637
Months between diagnosis and end of 
treatment
7·0 
(5·7–11·7)
6·1 
(5·4–7·1)
12·1 
(10·9–13·6)
Treatment adherence*
No 226 (13·1%) 125 (11·5%) 101 (15·9%)
Yes 1500 (86·9%) 964 (88·5%) 536 (84·1%)
Cure
No (death, transfer of health unit, default) 169 (9·8%) 94 (8·6%) 75 (11·8%)
Yes 1557 (90·2%) 995 (91·4%) 562 (88·2%)
Data are n, n (%), or median (IQR). *Completing the minimum number of doses (at least six for paucibacillary cases and 
at least 12 for multibacillary cases).
Table 2: Treatment duration, adherence, and cure in patients newly diagnosed with leprosy registered in 
the 100 Million Brazilian Cohort from 2007 to 2014, according to operational disease classification
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It is well established that leprosy treatment outcomes are 
affected by factors related to socioeconomic status and 
health services (ie, quality and access). A 2013 systematic 
review identified illiteracy, low monthly per-capita income, 
low socioeconomic status, and poor knowledge of the 
disease as key factors related to leprosy treatment dropout.7 
Additional factors include living in small households, 
migration, and working under precarious conditions.3 
Given that more deprived individuals are more likely to 
receive benefits from the PBF, we would expect that those 
individuals, in the absence of PBF (as a counterfactual), 
would have had inferior rather than superior (as observed 
in our study) probabilities of adherance to multidrug 
therapy and of cure.
In Brazil, PBF has been shown to have a positive effect 
on various socioeconomic indicators through increased 
food security, educational attainment, and general 
improvement of the economic conditions of the house-
hold.32–34 Further more, although the PBF includes 
health-related and education-related conditions targeting 
children aged 0–7 years and pregnant and lactating 
women (ie, vaccinations, routine medical check-ups, and 
enrolment and attendance in school), the effect of 
increased use of health care has been suggested to extend 
beyond the individuals directly targeted by the pro-
gramme.35 Although it is plausible that families who 
adhere to the PBF conditionalities are more likely than 
those who do not receive PBF aid to comply with a 
leprosy treatment programme, we would not expect this 
relationship to substantively confound the observed 
associations because families are eligible for the PBF 
benefit on the basis of their socio economic need and will 
only lose the PBF benefit at a minimum of 2 years of 
non-compliance with the conditions. Therefore, PBF 
receipt in the beneficiary group of our study does not 
correlate directly with individual families’ compliant 
behaviours during the timescale of our analysis. 
Moreover, evidence from other social programmes, such 
as the initiatives in Mexico and Liberia, suggests that 
conditional cash transfers might have other ancillary 
benefits, such as reduced migration and improved access 
to health care, which could facilitate treatment 
adherence.31,36 Further more, although the amount of 
cash transfered is small (BRL77–336 [$19–84] per family 
in 2014), preli minary evidence suggests that conditional 
cash transfer programmes can alleviate the financial 
burden of families affected by leprosy, similar to what 
has been observed in those affected by tuberculosis.6,37
In 2016, a randomised trial in tuberculosis-affected 
households in Peru showed that those receiving cash 
transfers were 12% less likely to incur out-of-pocket 
tuberculosis-related expenses that led to impoverishment 
than those who did not receive transfers.37 Another 
mechanism by which the PBF might directly improve 
treatment adherence is through the conditionality related 
to child attendance at routine health check-ups. In our 
analysis, the point estimates for the association between 
PBF receipt and treatment adherence and cure were 
Propensity score matched analysis IPTW analysis
Total Paucibacillary Multibacillary Total Paucibacillary Multibacillary
Overall population
Patients, n 17 302 7710 9336 11 456 5140 6316
Treatment adherence*
Non-beneficiaries 1·00 1·00 1·00 1·00 1·00 1·00
Beneficiaries 1·22 
(1·01–1·48)
1·37 
(0·98–1·91)
1·37 
(1·08–1·74)
1·31 
(1·10–1·56)
1·29 
(0·98–1·71)
1·38 
(1·10–1·73)
Cure
Non-beneficiaries 1·00 1·00 1·00 1·00 1·00 1·00
Beneficiaries 1·26 
(1·01–1·58)
1·12 
(0·75–1·67)
1·43 
(1·09–1·90)
1·24 
(1·00–1·52)
1·11 
(0·79–1·55)
1·36 
(1·05–1·77)
Children younger than 15 years
Patients, n 2654 1466 722 1726 1089 637
Treatment adherence*
Non-beneficiaries 1·00 1·00 1·00 1·00 1·00 1·00
Beneficiaries 1·55 
(0·89–2·68)
1·91 
(0·93–3·92)
1·47 
(0·62–3·48)
1·71 
(0·95–3·09)
1·77 
(0·82–3·81)
1·41 
(0·60–3·31)
Cure
Non-beneficiaries 1·00 1·00 1·00 1·00 1·00 1·00
Beneficiaries 1·57 
(0·83–2·97)
1·08 
(0·41–2·82)
1·68 
(0·67–4·24)
1·70 
(0·84–3·43)
1·34 
(0·48–3·72)
1·55 
(0·61–3·99)
Data are n or OR (95% CI). The average treatment effect on the treated was estimated in the propensity score matched primary analysis and the IPTW sensitivity analysis. 
OR and 95% CI estimated using logistic regression with further adjustment for income. IPTW=inverse probability of treatment weighting. PBF=Programa Bolsa Família. 
*Completing the minimum number of doses (at least six for paucibacillary cases and at least 12 for multibacillary cases).
Table 3: Average treatment effect of PBF aid on leprosy treatment adherence and cure for the study cohort (Brazil, 2007–14)
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higher in children younger than 15 years than in 
the overall population (table 3). Nevertheless, these 
associations were not significant, which might be 
explained by the small sample size and low frequency of 
study outcomes. Future research is needed to investigate 
why the point estimates for children were higher than 
those for the overall population. Overall, the association 
of PBF with leprosy treatment adherence and cure is 
compatible with the theory that social development was 
one of the main mechanisms responsible for leprosy 
elimination in the first half of the 20th century in high-
income countries.38
Our study was possible because of the use of nationwide 
linked datasets and the relatively high endemicity 
of leprosy in Brazil, enabling us to study more than 
11 000 patients with leprosy. Because of the large sample 
size, we were able to stratify by type of leprosy 
(paucibacillary and multibacillary), which affects the 
treatment durations. The large sample size also allowed 
us to investigate the effect of PBF on leprosy treatment 
outcomes in children, a group of high priority in leprosy 
control strategies. As the 100 Million Brazilian Cohort 
contained information about the poorest families in the 
Brazilian population, our study was a unique opportunity 
to study a social protection policy targeting this group 
and verify its effect on a disease that primarily affects the 
poorest and most vulnerable population of the country. 5,8
There are, however, limitations to our study. First, as 
expected using secondary data, the proportion of missing 
data for variables, such as education and work status, was 
notable (>10%). To account for missing data as a potential 
confounder, we included a missing category for indi-
vidual sociodemographic variables. Nevertheless, com-
plete case analysis showed weakened associations 
between PBF receipt and treatment adherence or cure, 
but with similar point estimates for patients with 
multibacillary disease, suggesting that the exclusions for 
missing data did not substantially alter our findings for 
multibacillary cases. Although we were able to control 
for the key socio demographic confounders, residual 
confounding is possible because data on other factors 
related to treatment adherence, including behavioural 
characteristics (eg, drug use and alcohol misuse) and 
access to and quality of health services (eg, distance to 
clinic or skill and pre paredness of health professionals), 
were not available in the routinely collected datasets 
linked in this cohort.7,16
In conclusion, our findings suggest that tackling 
adverse socioeconomic factors in patients with leprosy 
should be central to strategies for improving cure rates 
and ultimately eliminating the disease. We provide 
new evidence that programmes such as the PBF, which 
directly support patients of low socioeconomic status, 
have the potential to improve treatment adherence and 
cure in patients with leprosy. In the context of political 
instability and implementation of several austerity 
measures in Brazil, including the exclusion of more than 
1 million families from the PBF in 2017, budget 
restrictions to the Brasil sem Miséria social programme 
implemented in 2011, which complements the benefits 
from PBF, and the Constitutional Amendment 95 (EC95) 
in 2016, which limits any real growth in federal expen-
ditures on public health care for the next 20 years, social 
security in Brazil is under threat,39 which might 
jeopardise the indisputable health gains achieved from 
PBF’s implementation to date.40 Therefore, on the basis 
of the evidence provided by our study, we recommend 
that poverty-alleviating programmes, such as the PBF, 
should be viewed not only as essential tools to improve 
the wellbeing of poor families in Brazil, but also as 
essential components of WHO’s Global Leprosy Strategy 
2016–2020, which advocates for access to social and 
financial support services and strengthened relationships 
between patients and health services.1 Additionally, 
these programmes should be considered as important 
contributors to the achievement of the Sustainable 
Development Goals for neglected tropical diseases 
(goal 3, target 3.3).
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